- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT01715623
Polymorphism of the IgH Locus Regulatory Region as a Prognostic Factor During Immune Pathologies. (PRIERR)
The investigators previously showed that both antibody class switching (from IgM to IgG, IgA or IgE) and antibody secretion are controlled by a polymorphic "3' regulatory region" (3'RR) of the immunoglobulin heavy chain (IgH) locus. Alleles of the 3'RR have shown influences on the severity and progression of IgA nephropathy (IgAN) (with an over-representation of the B allele among patients with severe kidney IgA deposits). Allele B also constitutes a risk factor for celiac disease, herpetiform dermatitis, psoriasis and rheumatoid arthritis. Since the 3'RR now appears as a crucial regulator of Ig production, we wish to check whether its genetic polymorphism might influence not only the occurrence of immunopathologic processes involving class-switched antibody deregulated production but also the severity of such diseases or the time course of their progression. We wish to focus on two conditions involving class-switched antibodies: on one hand the severe forms of IgE hypersensitivities, and on the other hand a disease involving pathogenic IgA and for which the prognosis is currently very difficult to predict at the onset of the disease: Henoch-Schonlein purpura (HSP).
Regarding hypersensitivities, the diversity of their clinical manifestations prompt us to focus on homogeneous groups of patients and we thus wish to concentrate on two groups of patients who are frequently referred to the hospital: severe allergies to Hymenoptera venoms and severe food allergies related to peanut allergens sensitization. These groups will be built by considering multiple clinical criteria (clinical history, severity of the manifestations, positive skin tests, and positive oral provocation tests for peanut allergens…) and biological criteria authenticating the mechanisms of the disease (high specific serum IgE, demonstration of specific basophil activation by the allergen…).
In parallel to the study in patients, we will include a large cohort of healthy controls (400 individuals), in order to be able to decipher whether correlations can be seen between:
- IgH 3'RR genotypes
- The serum accumulation of the various Ig classes, including IgG subclasses, IgA (which are sometimes depicted as protective, sometimes as tolerogenic and anti-inflammatory) and IgE (highly pro-inflammatory and responsible for hypersensitivities)
- IgG allotypes (with 6 frequent IgG haplotypes known in human and previously reported as correlated with varying levels of IgG and IgE production in normal individuals).
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Yksityiskohtainen kuvaus
This study should thus finally provide answers to 5 questions which are currently un-addressed:
- How the 3'RR alleles are linked to IgG allotypes and corresponding IgH haplotypes?
- Is there a physiological link between 3'RR alleles and production of the various Ig classes and sub-classes?
- Is the 3'RR polymorphism connected with the risk of more severe forms of allergic diseases?
- Is the 3'RR polymorphism connected with the risk of occurrence and/or severe evolution of HSP?
- Is the oncogenicity of translocations affecting the IgH locus connected to the strength of the 3'RR allelic variants?
Opintotyyppi
Ilmoittautuminen (Todellinen)
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Limoges, Ranska, 87042
- Clinical Investigation Center
-
Limoges, Ranska, 87042
- Nephrology
-
Limoges, Ranska, 87042
- Pediatric
-
Limoges, Ranska, 87042
- Pneumology
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Näytteenottomenetelmä
Tutkimusväestö
4 populations :
- Healthy Volunteers
- subjects with HPS
- subjects with peanut allergy or hymenoptera venom allergy
- lymphoma (biological collection)
Kuvaus
Inclusion Criteria:
- Healthy Volunteers:
Age ≥ 18 and < 50 years No history of allergy, haematological malignancies or immune diseases
- Subjects with allergy:
- Children:
Age ≥ 4 and < 18 years Clinical history supporting the diagnosis of severe food allergy Peanut specific IgE (Arah2) -Adults: Age > 18 and < 60 years History of severe reaction after antigenic challenge Anaphylactic shock already experienced Specific IgE or positive BAT Positive prick tests
- subject with HPS:
- Children:
Age ≥ 4 and < 18 years Henoch Schonlein Purpura (HSP) documented by Ankara 2008 criteria
-Adult: Henoch Schonlein Purpura(HSP) with renal involvement Adults ≥ 18 years,
Exclusion Criteria:
- subject with allergy or subject with Henoch Schonlein Purpura(HSP): known pregnancy patient under guardianship
- Healthy Volunteers:
Allergy known pregnancy patient under guardianship
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
Kohortit ja interventiot
Ryhmä/Kohortti |
Interventio / Hoito |
---|---|
Children with HSP
children with Purpura of Henoch-Schönlein with or without renal complication
|
Dosage of Ig
|
healthy volunteers
healthy volunteers without allergy
|
Dosage of Ig
|
subjects with allergy
subjects with peanut allergy or hymenoptera venom allergy
|
Dosage of Ig
|
lymphoma
lymphoma-proliferation with chromosome 14 translocation
|
Dosage of Ig
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
the percentage of allele B
Aikaikkuna: one day
|
A comparison will be made of the percentage of allele B between healthy volunteers and the three cohorts of subjects with various diseases: (1) lymphoma (lymphoma-proliferation with chromosome 14 translocation ), (2) Henoch-Schonlein purpura HSP (3), allergy (peanut and Hymenoptera venom)
|
one day
|
Yhteistyökumppanit ja tutkijat
Sponsori
Yhteistyökumppanit
Tutkijat
- Päätutkija: Michel COGNE, MD, Limoges UH
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muut tutkimustunnusnumerot
- I12002 PRIERR
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset a blood sample
-
Hillel Yaffe Medical CenterTuntematon
-
Thomas Jefferson UniversityRekrytointiRelapse Remitting multippeliskleroosiYhdysvallat
-
Natera, Inc.Eunice Kennedy Shriver National Institute of Child Health and Human Development... ja muut yhteistyökumppanitLopetettuAneuploidia | Trisomia 21 | Trisomia 18 | Trisomia 13Yhdysvallat, Irlanti, Kanada, Italia, Korean tasavalta, Espanja
-
University of PittsburghValmis
-
University of California, DavisValmis
-
Ohio State UniversityPeruutettuTerveet yksilötYhdysvallat
-
Children's Hospital Los AngelesRekrytointiLasten kiinteä kasvain, määrittelemätön, protokollakohtainenYhdysvallat
-
Anthony MaglioccoMontefiore Medical Center; University of Saskatchewan; DHR Health Institute... ja muut yhteistyökumppanitRekrytointi
-
Lawson Health Research InstituteUniversity of Toronto; University of Western Ontario, Canada; MOUNT SINAI... ja muut yhteistyökumppanitRekrytointi
-
Intermountain Health Care, Inc.Rekrytointi